Qpex Biopharma
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6275 Nancy Ridge Dr Ste 100, San Diego, ...Phone Number
(858) 500-8366Website
www.qpexbio.comRevenue
$5.6 MillionIndustry
About Qpex Biopharma
Qpex Biopharma Org Chart
Vice President, Program Management
Is Qpex Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Qpex Biopharma had a recent Job posting/layoffs
Product Launch: Get notified when Qpex Biopharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Qpex Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Qpex Biopharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Qpex Biopharma is spiking on competitors!
Earning: See what the market has to say on Qpex Biopharma recently announced quarterly report
Funding: Get notified immidiatlly once Qpex Biopharma has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Qpex Biopharma
Recommended Actions
Reach out to Masked Content who joined Qpex Biopharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Qpex Biopharma
Compare insights from companies similar to Qpex Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Qpex Biopharma
Company Profile Activity
Activity Insights
Qpex Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Qpex Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Qpex Biopharma.
Qpex Biopharma financials insights
Gather financial insights about Qpex Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$33M
Unspecified
$20M
Qpex Biopharma Tech Stack
A closer look at the technologies used by Qpex Biopharma
Most Recent Scoops
Qpex Biopharma News & Media
Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting
SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23. The presentations will describe progress on three Qpex investigational products that the recent WHO pipeline analysis identified as addressing drug-resistant pathogens for which there is a critical need for new drugs. IQpex Biopharma Announces Presentation of Clinical Data for Ultra-Broad Spectrum β-lactamase Inhibitor Xeruborbactam and the Lipopeptide QPX9003 at ECCMID 2022 Meeting
SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma, Inc. (Qpex), a clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced the company will present new clinical data for their β-lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held on April 23-26, 2022. “We are excited to present initial results from our PhQpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens
SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma, Inc., (Qpex) an antibiotic resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, today announced research published in Nature Communications on the discovery and preclinical properties of QPX9003, a new synthetic lipopeptide antibiotic that is distinct from existing polymyxin-type antibiotics. The paper, “A synthetic lipopeptide targeting top-priority multidrug-resistant gram-negati
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Qpex Biopharma
Qpex Biopharma is a medical company for infectious diseases. Qpex Biopharma was founded in 2018 and is headquartered in San Diego, California.... Read More